Janssen’s Tremfya shows long-term efficacy in moderate to severe plaque psoriasis
pharmafile | February 19, 2018 | News story | Research and Development, Sales and Marketing | Janssen, Tremfyam guselkumab, pharma, plaque psoriasis, psoriasis
Janssen has unveiled new Phase 3 trial data for its IL-23 inhibitor Tremfya (guselkumab), demonstrating that the drug was able to generate high skin clearance rates in patients with moderate to severe plaque psoriasis when administered as a long-term treatment.
The data from the 992-strong trial showed that, of the participants who achieved a 90% improvement in skin clearance according to the Psoriasis Area and Severity Index (PASI 90) at week 28, 86% went on to maintain the same level of response with continuous treatment through to week 72. This is compared to just 11.5% of the 173 patients who maintained the same level of response after being withdrawn from continued treatment with the drug. Of the total number of patients withdrawn, 87.6% achieved a PASI 90 response within six months of starting treatment.
Tremfya was most recently approved in Europe as a treatment for moderate to severe plaque psoriasis in adult patients who may benefit from systemic therapy.
“The longer-term data from VOYAGE 2 shows promising results for guselkumab as both a continuous, long-term treatment for moderate to severe plaque psoriasis, and as an option for patients who have been withdrawn from therapy and retreated,” commented study investigator Professor Kristian Reich of Dermatologikum Berlin and SCIderm Research Institute. “These data provide important information to dermatologists should they need to interrupt treatment with guselkumab for a period of time, as the findings demonstrate guselkumab quickly and robustly re-established a PASI 90 response within six months.”
Matt Fellows
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
